07-24-06

HW

Express Mail No. EV475142808US

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan et al.

Confirmation No.: 3565

Application No.: 10/657,006

Group Art Unit: 1644

Filed: September 5, 2003

Examiner: Skelding, Zachary S.

For: METHODS OF PREVENTING OR

Attorney Docket No.: 10271-116-999

TREATING T CELL MALIGNANCIES BY ADMINISTERING CD2

**ANTAGONISTS** 

## RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 C.F.R. § 1.142

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed June 21, 2006, in which the Examiner imposed a restriction requirement, and in accordance with Rule 142 of the Rules of Practice, please consider and enter the following remarks.

It is believed that no fee is due in connection with the filing of this Response. However, in the event that a fee is required, please charge such fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Listing of Claims begins on page 2 of this paper.

Remarks begin on page 7 of this paper.